Millipore Corporation has announced that it has entered into a worldwide, non-exclusive license agreement with Bayer HealthCare AG, a subsidiary of Bayer AG, to use Millipore’s UCOE™ (Ubiquitous Chromatin Opening Element) technology to manufacture its biologic drugs.
The license will enable Bayer to efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations. Financial terms were not disclosed.
The process of manufacturing biologic drugs such as recombinant proteins often begins with growing mammalian cells in a bioreactor. These cells act as “factories” and produce the proteins that form the basis of biologic drugs. Millipore’s UCOE technology helps biopharmaceutical companies to identify which cells will be the most effective in producing proteins during large-scale manufacturing.
“We have built successful relationship with Bayer over a number of years, and we are excited about their commitment to the UCOE technology,” said Andrew Bulpin, Ph.D., Vice President of Millipore’s Upstream Bioprocessing Business Unit. “This license is another example of how we can help pharmaceutical and biotech companies efficiently manufacture biologic drugs for both commercial use and for use in clinical development.